Marshall Wace North America’s Atara Biotherapeutics ATRA Stock Holding History

Marshall Wace North America’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-632	Closed	-$227K	–	1446
2021 Q1	$227K	Sell	632 -14,109	-96%	-$6.24M	﹤0.01%	1383
2020 Q4	$7.23M	Buy	+14,741	New	+$6.8M	0.03%	454
2020 Q3	–	Sell	-3,926	Closed	-$1.43M	–	1198
2020 Q2	$1.43M	Buy	+3,926	New	+$992K	0.01%	666
2019 Q2	–	Sell	-1,973	Closed	-$1.96M	–	1147
2019 Q1	$1.96M	Buy	+1,973	New	+$1.83M	0.01%	516
2018 Q1	–	Sell	-481	Closed	-$218K	–	1415
2017 Q4	$218K	Buy	+481	New	+$178K	﹤0.01%	1275
2017 Q3	–	Sell	-1,214	Closed	-$425K	–	1247
2017 Q2	$425K	Buy	+1,214	New	+$468K	﹤0.01%	1116

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Marshall Wace North America's ATRA Position: Q2 2021 in Review

Marshall Wace North America sold out of Atara Biotherapeutics (ATRA) in Q2 2021, closing a stake of 632 shares — an estimated $227K sold.

Marshall Wace North America first reported a position in ATRA in Q2 2017 and held it in 6 quarters. The position peaked at $7.23M in Q4 2020. 145 funds tracked by Wall St. Rank hold ATRA as of Q2 2021.

Marshall Wace North America reported no remaining Atara Biotherapeutics position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 632 Atara Biotherapeutics shares in Q2 2021, an estimated $227K.
Marshall Wace North America first reported a position in Atara Biotherapeutics in Q2 2017 and held it in 6 quarters.
Marshall Wace North America's Atara Biotherapeutics position peaked at $7.23M in Q4 2020.
145 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.